Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CAR T-REX

Financiado

Cerrado

CAR T cells Rewired to prevent EXhaustion in the tumour microenvironment

Although immunotherapy of select hematological malignancies using Chimeric Antigen Receptor (CAR) redirected T lymphocytes has recently gained regulatory approval, successful treatment of solid tumors using CAR T cells remains elu... ver más

31/03/2027

STEMMATTERS

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

STEMMATTERS BIOTECNOLOGIA E MEDICIINA REGENER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 5 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-12-16

HORIZON-EIC-2022-PATHFINDEROPEN-01-01: EIC Pathfinder Open 2022 Scope:You should apply to this call if you are looking for support from EIC Pathfinder Open to reali...

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

STEMMATTERS

783.24K€ | Lider

UNIVERSITY OF DEBRECEN DE

N.D. | Participante

USC

560.51K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

T-FITNESS FINE-TUNING T CELL NETWORKS OF EXHAUSTION BY SYNTHETIC SENSO... 4M€ Cerrado

TRAP-CART Tumor targeting through a TME specific regulatory code and p... 174K€ Cerrado

THAT IS HUNT Triggering Haematological Adoptive T cell Immunotherapy Stra... 168K€ Cerrado

ATECT Advanced T cell Engineered for Cancer Therapy 8M€ Cerrado

PolyAntiTumor Polyclonal anti-tumor immunity by engineered human T cells 2M€ Cerrado

CNS2023-144487 Inmunidad, infección e inmunoterapia 200K€ Cerrado

Duración del proyecto: 51 meses Fecha Inicio: 2022-12-16
Fecha Fin: 2027-03-31

Líder del proyecto

STEMMATTERS BIOTECNOLOGIA E MEDICIINA REGENER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Although immunotherapy of select hematological malignancies using Chimeric Antigen Receptor (CAR) redirected T lymphocytes has recently gained regulatory approval, successful treatment of solid tumors using CAR T cells remains elusive. One salient problem is the limited efficacy and untimely exhaustion of CAR T cells in the tumor microenvironment (TME). Combining innovative methods of genome editing, chemistry and immunology, CAR T-REX proposes to explore a novel concept of building auto-regulated genetic circuits into CAR T cells to selectively circumvent their exhaustion upon activation in the TME. Genetic rewiring will be achieved by precisely inserting artificial miRNAs under endogenous exhaustion-related Driver promoters to downregulate Target genes that cause exhaustion. Proprietary technology enables specific replacement of the Driver gene without risking off-target mutations. Further advantages of combined insertion and silencing are (i) the ability to regulate when a gene is turned on/off by biologically and clinically relevant cellular cues, and (ii) multiple gene-knockdown with a single dsDNA cleavage and RNA-silencing of both alleles. These genetic modifications will be implemented using a novel high-performance peptide-based gene delivery platform with unlimited loading capacity, allowing combination of several types of cargo, as well as economical large scale GMP production. Rewired HER2/Neu (ErbB2) redirected CAR T cells will be tested on preclinical breast and gastric carcinomas, and variants that eliminate tumors resistant to conventional 2nd and 3rd generation peers (without adverse events) will be developed/manufactured following quality-by-design principles under GMP-like conditions, thus accelerating the pathway towards clinical translation. These approaches will also constitute a proof-of-concept for modifying therapeutic cell products, with the potential to considerably improve their safety, specificity, efficacy, scalability and cost.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores